Cargando…

Fimasartan, an angiotensin II receptor antagonist, ameliorates an in vivo zebrafish model of heart failure

BACKGROUND/AIMS: Angiotensin II in the failing heart initially helps to maintain cardiac output and blood pressure, but ultimately accelerates its deterioration. In this study, we established a model of arrhythmia-induced heart failure (HF) in zebrafish and investigated the role of renin-angiotensin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Quan, Hailian, Oh, Gyu Chul, Seok, Seung Hyeok, Lee, Hae-Young
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Association of Internal Medicine 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7652659/ https://www.ncbi.nlm.nih.gov/pubmed/32164398 http://dx.doi.org/10.3904/kjim.2019.038

Ejemplares similares

A Novel Angiotensin Type I Receptor Antagonist, Fimasartan, Prevents Doxorubicin-induced Cardiotoxicity in Rats
por: Chang, Sung-A, et al.
Publicado: (2015)

Efficacy of fimasartan/hydrochlorothiazide combination in hypertensive patients inadequately controlled by fimasartan monotherapy
por: Rhee, Moo-Yong, et al.
Publicado: (2015)

Clinic and Home Blood Pressure Lowering Effect of an Angiotensin Receptor Blocker, Fimasartan, in Postmenopausal Women with Hypertension
por: Kim, Song-Yi, et al.
Publicado: (2016)

Placental transfer and mammary excretion of a novel angiotensin receptor blocker fimasartan in rats
por: Kim, Tae Hwan, et al.
Publicado: (2016)

Fimasartan-induced liver injury in a patient with no adverse reactions on other types of angiotensin II receptor blockers: A case report
por: Park, Dae Hwa, et al.
Publicado: (2017)

Comparison Between Fimasartan Versus Other Angiotensin Receptor Blockers in Patients With Heart Failure After Acute Myocardial Infarction
por: Kim, Jihoon, et al.
Publicado: (2023)

Angiotensin II Type 1 Receptor Blocker, Fimasartan, Reduces Vascular Smooth Muscle Cell Senescence by Inhibiting the CYR61 Signaling Pathway
por: Kim, Inho, et al.
Publicado: (2019)

Long-Term Safety of a Novel Angiotensin Receptor Blocker, Fimasartan, According to the Absence or Presence of Underlying Liver Disease in Korean Hypertensive Patients: A Prospective, 12-Month, Observational Study
por: Oh, Gyu Chul, et al.
Publicado: (2020)

Cardioprotective Effect of Fimasartan, a New Angiotensin Receptor Blocker, in a Porcine Model of Acute Myocardial Infarction
por: Sim, Doo Sun, et al.
Publicado: (2015)

Fimasartan for independent reduction of blood pressure variability in mild-to-moderate hypertension
por: Shin, Mi-Seung, et al.
Publicado: (2016)

The efficacy and safety of co-administration of fimasartan and rosuvastatin to patients with hypertension and dyslipidemia
por: Rhee, Moo-Yong, et al.
Publicado: (2017)

Fimasartan-Based Blood Pressure Control after Acute Cerebral Ischemia: The Fimasartan-Based Blood Pressure Control after Acute Cerebral Ischemia Study
por: Hong, Keun-Sik, et al.
Publicado: (2021)

Pharmacokinetic and bioequivalence study comparing a fimasartan/rosuvastatin fixed-dose combination with the concomitant administration of fimasartan and rosuvastatin in healthy subjects
por: Kang, Woo Youl, et al.
Publicado: (2018)

Comparison of fimasartan and amlodipine therapy on carotid atherosclerotic plaque inflammation
por: Oh, Minyoung, et al.
Publicado: (2018)

Fimasartan versus perindopril with and without diuretics in the treatment of elderly patients with essential hypertension (Fimasartan in the Senior Subjects (FITNESS)): study protocol for a randomized controlled trial
por: Kang, Min-gu, et al.
Publicado: (2019)

Development of a Zebrafish Larvae Model for Diabetic Heart Failure With Reduced Ejection Fraction
por: Kim, Inho, et al.
Publicado: (2022)

Fimasartan reduces clinic and home pulse pressure in elderly hypertensive patients: A K-MetS study
por: Cho, Eun Joo, et al.
Publicado: (2019)

A randomized, double-blind, multicenter, phase III study on the efficacy and safety of a combination treatment involving fimasartan, amlodipine, rosuvastatin in patients with essential hypertension and dyslipidemia who fail to respond adequately to fimasartan monotherapy
por: Jeon, Eun-Seok, et al.
Publicado: (2022)

Fimasartan for Remodeling after Myocardial Infarction
por: Lim, Byung-Kwan, et al.
Publicado: (2019)

Fimasartan Ameliorates Deteriorations in Glucose Metabolism in a High Glucose State by Regulating Skeletal Muscle and Liver Cells
por: Jang, Yoo Na, et al.
Publicado: (2022)

PPARγ Agonist and Angiotensin II Receptor Antagonist Ameliorate Renal Tubulointerstitial Fibrosis
por: Han, Jee-Young, et al.
Publicado: (2010)

Pharmacokinetic interaction between fimasartan and atorvastatin in healthy male volunteers
por: Choi, Yewon, et al.
Publicado: (2018)

Fimasartan: A new armament to fight hypertension
por: Pradhan, Akshyaya, et al.
Publicado: (2019)

Fimasartan Ameliorates Nonalcoholic Fatty Liver Disease through PPARδ Regulation in Hyperlipidemic and Hypertensive Conditions
por: Lee, Yong-Jik, et al.
Publicado: (2017)

A Pharmacokinetic Drug Interaction Between Fimasartan and Linagliptin in Healthy Volunteers
por: Kang, Woo Youl, et al.
Publicado: (2020)

Combination therapy with an angiotensin‐converting‐enzyme inhibitor and an angiotensin II receptor antagonist ameliorates microinflammation and oxidative stress in patients with diabetic nephropathy
por: Nakamura, Akihiko, et al.
Publicado: (2012)

Fimasartan, a Novel Angiotensin-Receptor Blocker, Protects against Renal Inflammation and Fibrosis in Mice with Unilateral Ureteral Obstruction: the Possible Role of Nrf2
por: Kim, Soojeong, et al.
Publicado: (2015)

Comparison of the effects of empagliflozin and sotagliflozin on a zebrafish model of diabetic heart failure with reduced ejection fraction
por: Kim, Inho, et al.
Publicado: (2023)

Eprosartan mesylate, an angiotensin II receptor antagonist
por: Qian, Jing-Jing, et al.
Publicado: (2011)

The influence of dietary sodium content on the pharmacokinetics and pharmacodynamics of fimasartan
por: Gu, Namyi, et al.
Publicado: (2016)

Pharmacokinetic comparison between a fixed-dose combination of fimasartan/amlodipine/hydrochlorothiazide 60/10/25 mg and a corresponding loose combination of fimasartan/amlodipine 60/25 mg and hydrochlorothiazide 25 mg in healthy subjects
por: Jung, Jihyun, et al.
Publicado: (2021)

Safety and Efficacy of Fimasartan in Patients with Arterial Hypertension (Safe-KanArb Study): An Open-Label Observational Study
por: Park, Jeong Bae, et al.
Publicado: (2013)

Decreased potency of fimasartan in liver cirrhosis was quantified using mixed-effects analysis
por: Kim, Choon OK, et al.
Publicado: (2017)

Angiotensin-(1-9) ameliorates pulmonary arterial hypertension via angiotensin type II receptor
por: Cha, Seung Ah, et al.
Publicado: (2018)

Improving vagal activity ameliorates cardiac fibrosis induced by angiotensin II: in vivo and in vitro
por: Liu, Jin-Jun, et al.
Publicado: (2015)

Clemizole and La(3+) salts ameliorate angiotensin II‐induced glomerular hyperpermeability in vivo
por: Dolinina, Julia, et al.
Publicado: (2021)

Regional Absorption of Fimasartan in the Gastrointestinal Tract by an Improved In Situ Absorption Method in Rats
por: Kim, Tae Hwan, et al.
Publicado: (2018)

Fimasartan attenuates renal ischemia-reperfusion injury by modulating inflammation-related apoptosis
por: Cho, Jang-Hee, et al.
Publicado: (2018)

Fimasartan ameliorates renal ischemia reperfusion injury via modulation of oxidative stress, inflammatory and apoptotic cascades in a rat model
por: Abbas, Weaam, et al.
Publicado: (2022)

Zebrafish Model to Study Angiotensin II-Mediated Pathophysiology
por: Joshi, Bhagyashri, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_c48nt70h0uus5vtj2f0b5m6nj6